Palatin Technology / voraussichtliches Marktpotential von 1,3 Mrd $ bis 2020 allein in USA (Seite 575)
eröffnet am 17.02.15 22:17:27 von
neuester Beitrag 28.02.24 20:50:54 von
neuester Beitrag 28.02.24 20:50:54 von
Beiträge: 5.764
ID: 1.207.859
ID: 1.207.859
Aufrufe heute: 6
Gesamt: 1.024.324
Gesamt: 1.024.324
Aktive User: 0
ISIN: US6960775020 · WKN: A3DTUW · Symbol: PTN
1,7460
EUR
-6,13 %
-0,1140 EUR
Letzter Kurs 21:03:50 Tradegate
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0450 | +14.021,62 | |
| 40,80 | +100,00 | |
| 6,8900 | +30,00 | |
| 1,7870 | +28,56 | |
| 37,22 | +22,39 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,8165 | -26,67 | |
| 1,7000 | -31,17 | |
| 2,2450 | -33,58 | |
| 2,7450 | -38,66 | |
| 3,5500 | -55,46 |
Beitrag zu dieser Diskussion schreiben
Feedback
NEWS!!! http://finance.yahoo.com/news/amag-pharmaceuticals-palatin-t… this is a 465 million 
deal add it up NEUBEWERTUNG!!!
deal add it up NEUBEWERTUNG!!!
Antwort auf Beitrag Nr.: 53.617.650 von GelsenSzene am 04.11.16 08:06:42Kennt jemand den Grund für den erneuten Kurssturz?
Sorry aber das ist mein letzter Beitrag hier, ich wollte Palatin nicht pushen, aber ein Wert der ein solches Potential wie vergleichsweise Viagra hat und die Phase 3 der FDA erfolgreich abgeschlossen und dann nicht tagelang nach oben läuft habe ich noch nie erlebt. Schade aber man lernt im Leben immer wieder hinzu. An den beiden letzten Tagen waren über 1,6 Mio. shares short das Volumen lag gestern bei 53% aller trades, dass sind schon Hausnummern
. Der Wert ist erstmal Tod, es sei denn es kommt eine Meldung über eine Partnerschaft oder einen Buyout. Dann gibt es einen short-squeeze und das Teil geht durch die Decke. Momentan kennt der BioTech Sektor aber nur eine Richtung und die ist tief rot.
. Der Wert ist erstmal Tod, es sei denn es kommt eine Meldung über eine Partnerschaft oder einen Buyout. Dann gibt es einen short-squeeze und das Teil geht durch die Decke. Momentan kennt der BioTech Sektor aber nur eine Richtung und die ist tief rot.
Palatin Technologies, Inc. (PTN): Partnership Discussions Likely to Accelerate, Says Canaccord
Jason Cohen, Editor — November 2, 2016, 7:13 PM EDT
Canaccord analyst John Newman reiterated a Buy rating on shares of Palatin Technologies, with a price target of $6.00, which implies an upside of 953% from current levels.
Newman noted, “Palatin pre-specified n=9 secondary endpoints, for which data are not yet available, but we expect data including satisfying sexual events at an upcoming scientific meeting. Importantly, we believe that bremelanotide will show a statistically significant benefit for SSEs vs placebo, similar to what was demonstrated in the Phase 2b study, where bremelanotide showed an ~0.5 point increase.”
“We expect partnership discussions to accelerate, especially as additional data analyses for bremelanotide are available, with a partnership update possible by YE16. We believe Palatin is in a stronger position to execute a partnership as it reacquired ex-US rights from Gideon Richter previously. Importantly, Palatin believes a partner is optimal to unlock the full commercial potential for bremelanotide, although the company is fully capable of managing the NDA submission expected during 2H17,” Newman added.
Jason Cohen, Editor — November 2, 2016, 7:13 PM EDT
Canaccord analyst John Newman reiterated a Buy rating on shares of Palatin Technologies, with a price target of $6.00, which implies an upside of 953% from current levels.
Newman noted, “Palatin pre-specified n=9 secondary endpoints, for which data are not yet available, but we expect data including satisfying sexual events at an upcoming scientific meeting. Importantly, we believe that bremelanotide will show a statistically significant benefit for SSEs vs placebo, similar to what was demonstrated in the Phase 2b study, where bremelanotide showed an ~0.5 point increase.”
“We expect partnership discussions to accelerate, especially as additional data analyses for bremelanotide are available, with a partnership update possible by YE16. We believe Palatin is in a stronger position to execute a partnership as it reacquired ex-US rights from Gideon Richter previously. Importantly, Palatin believes a partner is optimal to unlock the full commercial potential for bremelanotide, although the company is fully capable of managing the NDA submission expected during 2H17,” Newman added.
der folgende Artikel stellt nochmal die Fakten klar. Ich halte bis zum ersten Quartal 2017, für mich das größte Potential für einen Buyout im gesamten BioTech Sektor.
Palatin Technologies, Inc. (PTN)’s Data Is Bullish, Whatever Other Analysts Say
Published on November 2, 2016 at 1:36 pm by Market Exclusive in News,Stock Analysis
Palatin Technologies, Inc. (NYSEMKT:PTN) is soaring on data released from its lead female libido trial. The company is up more than 30% mid morning in the US, having reached highs of a 56% gain at market open, and volume suggests we’re going to see further strength go the company’s way before the session draws to a close. Things aren’t as straight forward as they might initially seem, however.
The data seems to have played a bit loose with the predefined endpoints for the trial, and this is causing a little bit of uncertainty as to how markets should read into its interpretation......
.......Between then and now, the company has had repeated discussions with the agency regarding what is the most appropriate measurement of benefit. Based on public hearings, sponsor input, increased education, that sort of thing, the FDA and the company agreed that the two endpoints now used are the most appropriate. This was all arranged prior to database lock, so it’s perfectly acceptable and above board.
This database lock came around ten days prior to the agency’s guidance on the overall framework, and the fact that the revised endpoint falls in line with the latter is a plus, not a negative.
That’s essentially the core of this situation. When the trials kicked off, nobody really knew what was the best way to measure efficacy. Now the agency has put together a framework outlining (as best it can, it’s still early days) what it expects to measure clinical benefit against, and Palatin Technologies, Inc. (NYSEMKT:PTN) has amended its co-primaries to reflect these agency expectations.
So what’s next?
The company expects to get an NDA with the FDA during the second half of this year, but between now and then we should get a host of data relating to secondary endpoints (including the above discussed ex-primary). Each of these data points has the potential to serve up some bullish momentum, so we expect the trend to continue as we head into the end of the year and the first quarter of 2017.
Palatin Technologies, Inc. (PTN)’s Data Is Bullish, Whatever Other Analysts Say
Published on November 2, 2016 at 1:36 pm by Market Exclusive in News,Stock Analysis
Palatin Technologies, Inc. (NYSEMKT:PTN) is soaring on data released from its lead female libido trial. The company is up more than 30% mid morning in the US, having reached highs of a 56% gain at market open, and volume suggests we’re going to see further strength go the company’s way before the session draws to a close. Things aren’t as straight forward as they might initially seem, however.
The data seems to have played a bit loose with the predefined endpoints for the trial, and this is causing a little bit of uncertainty as to how markets should read into its interpretation......
.......Between then and now, the company has had repeated discussions with the agency regarding what is the most appropriate measurement of benefit. Based on public hearings, sponsor input, increased education, that sort of thing, the FDA and the company agreed that the two endpoints now used are the most appropriate. This was all arranged prior to database lock, so it’s perfectly acceptable and above board.
This database lock came around ten days prior to the agency’s guidance on the overall framework, and the fact that the revised endpoint falls in line with the latter is a plus, not a negative.
That’s essentially the core of this situation. When the trials kicked off, nobody really knew what was the best way to measure efficacy. Now the agency has put together a framework outlining (as best it can, it’s still early days) what it expects to measure clinical benefit against, and Palatin Technologies, Inc. (NYSEMKT:PTN) has amended its co-primaries to reflect these agency expectations.
So what’s next?
The company expects to get an NDA with the FDA during the second half of this year, but between now and then we should get a host of data relating to secondary endpoints (including the above discussed ex-primary). Each of these data points has the potential to serve up some bullish momentum, so we expect the trend to continue as we head into the end of the year and the first quarter of 2017.
Trading Spotlight
Antwort auf Beitrag Nr.: 53.606.535 von GelsenSzene am 02.11.16 16:56:49Der Typ ist bekannt für seine "Geschichten".
Ich könnte etliche Beispiele nennen, wo er die Finger im Spiel hatte....
Adam Feuerstein hatte es demzufolge auch wieder sehr eilig, vorbörslich seine Story zu platzieren.
Mit Erfolg, beinahe wäre PTN im Minus gelandet.
Rechne mit einem Schlusskurs > $0,70
Ich könnte etliche Beispiele nennen, wo er die Finger im Spiel hatte....
Adam Feuerstein hatte es demzufolge auch wieder sehr eilig, vorbörslich seine Story zu platzieren.
Mit Erfolg, beinahe wäre PTN im Minus gelandet.
Rechne mit einem Schlusskurs > $0,70
The reuters article does say PTN has received multiple offers from interested parties....., also wenn das stimmt, dann werfe ich nicht für ein paar % meine Shares weg, wenn es einen Bieterkampf gibt, sehe ich $$$ Zeichen am Horizont und Reuters ist nicht dafür bekannt unseriöse Gerüchte zu verbreiten
Adam Feuerstein hat mal wieder zugeschlagen, ich kenne den Verbrecher noch von Ariad:
Investigate falsifying article on PTN
Adam Feuerstein published an article saying "palatin's libido boosting drug failed frequency test" causing a panic sell on great results. Palatin reported positive results inline with FDA accepted endpoints. we need full investigation to be conducted on Adam's manipulation and lock him up. This is not the first time he manipulated stocks.
ich glaube das Teil wird die 1$ Marke sehr schnell nehmen.
Danke an den freundlichen Herrn der mir sein 40.000 shares für 0,52 Cent in Frankfurt verkauft hat.
Investigate falsifying article on PTN
Adam Feuerstein published an article saying "palatin's libido boosting drug failed frequency test" causing a panic sell on great results. Palatin reported positive results inline with FDA accepted endpoints. we need full investigation to be conducted on Adam's manipulation and lock him up. This is not the first time he manipulated stocks.
ich glaube das Teil wird die 1$ Marke sehr schnell nehmen.
Danke an den freundlichen Herrn der mir sein 40.000 shares für 0,52 Cent in Frankfurt verkauft hat.
Female Viagra developer Palatin Tech exploring potential sale .....not sure why I wouldn't invest in a company with successful phase 3 study and mgt. speaking of a likely buyout/partner by end of 2016. reuters article says PTN plans to finance next stage through partner/BO rather than equity issuance. Really like the sound of that....
ein par Stimmen von StockTwits
Bin auch dabei, habe 40k in Frankfurt geordert bei 0,52 geordert, halte bis zum Ende 2016 bei einem BO macht hier jeder seinen Schnitt
ein par Stimmen von StockTwits
Bin auch dabei, habe 40k in Frankfurt geordert bei 0,52 geordert, halte bis zum Ende 2016 bei einem BO macht hier jeder seinen Schnitt
Antwort auf Beitrag Nr.: 49.920.951 von gnaraloo79 am 05.06.15 18:43:35
http://stocktwits.com/symbol/PTN?q=PTN
Diskussion in USA
falls Interesse an der momentanen Diskussion in USA hier ein linkhttp://stocktwits.com/symbol/PTN?q=PTN
Durchsuchen
